Genmab Earns $10M Janssen Milestone

Genmab A/S has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, triggering a $10 million payment related to progress in the ongoing Phase III study (“CASTOR” MMY3004).
 
The Phase III study is evaluating daratumumab in combination with bortezomib and dexamethasone compared to bortezomib and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma. The primary endpoint of the study is progression free survival (PFS).
 
“We are very pleased with the firm progress being made in the daratumumab development program under the direction of our strategic partner Janssen. At Genmab we are committed to developing differentiated therapeutics to fight cancer, and it is therefore rewarding to see one of our antibodies moving rapidly through clinical development,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab.